Vimarsana
Biggest News Aggregation in the World

Page 4 - Including Selective News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Including Selective. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Including Selective Today - Breaking & Trending Today

Travere Therapeutics, Inc.: Travere Therapeutics Announces Interim Analysis from the Phase 3 PROTECT Study of FILSPARI (Sparsentan) in IgA Nephropathy Published in The Lancet and Presented at World Congress of Nephrology 2023 - Vimarsana News

Travere Therapeutics, Inc.: Travere Therapeutics Announces Interim Analysis from the Phase 3 PROTECT Study of FILSPARI (Sparsentan) in IgA Nephropathy Published in The Lancet and Presented at World Congress of Nephrology 2023

Published: April 1, 2023

SAN DIEGO, April 01, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced publication in The Lancet of the interim analysis of efficacy and safety data from the ongoing pivotal

Source: finanznachrichten.de
Related Topics:
United StatesKrung Thep MahanakhonNivi NehraNaomi EichenbaumBrad RovinEuropean UnionOhio State University CenterDivision For NephrologyExchange CommissionCorporate CommunicationsWorld CongressClinical Research ManagementCompany Annual Report On FormTravere Therapeutics IncMedical DirectorAbout IgaImportant SafetyEndothelin Receptor AntagonistsUpper LimitFetal ToxicityKidney InjuryAngiotensin SystemAcid Reducing AgentsSteroidal Anti Inflammatory AgentsIncluding Selective
Travere Therapeutics Announces Late-Breaker Presentations of the Interim Analysis from the Phase 3 PROTECT Study of FILSPARI™ (Sparsentan) in IgA Nephropathy at the ISN World Congress of Nephrology and NKF Spring Clinical Meetings 2023 - Vimarsana News

Travere Therapeutics Announces Late-Breaker Presentations of the Interim Analysis from the Phase 3 PROTECT Study of FILSPARI™ (Sparsentan) in IgA Nephropathy at the ISN World Congress of Nephrology and NKF Spring Clinical Meetings 2023

Published: March 23, 2023

SAN DIEGO, March 23, 2023 -- Travere Therapeutics, Inc. today announced that the interim analysis of efficacy and safety data from the ongoing Phase 3 PROTECT Study evaluating... | March 23, 2023

Source: marketscreener.com
Related Topics:
Krung Thep MahanakhonUnited StatesNivi NehraNaomi EichenbaumCompany Annual Report On FormEuropean UnionExchange CommissionCorporate CommunicationsBits AssociationWorld CongressTravere Therapeutics IncClinical MeetingsDual Endothelin Angiotensin Receptor AntagonistReduces ProteinuriaInterim ResultsLate Breaking ClinicalPlenary HallPatient Baseline CharacteristicsAsian RegionsYoung PatientsSustained Proteinuria ReductionSparsentan TreatmentLabel ExtensionDisease ProgressionIga Nephropathy